A Phase 1 Open-Label Multicenter Study to Assess the Safety Tolerability and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Brief description of study

If you have been diagnosed with solid tumors, either removed previously by surgery or unresectable (locally advanced or metastatic), you may qualify for this phase 1 study testing the investigational drug mRNA-4157 alone or in combination with pembrolizumab. The main goal of this study is to study the safety of these drugs, and how well the body deals with effects of mRNA-4157 alone or in combination with pembrolizumab and to find the best dose for future studies of mRNA-4157 when given alone or when given with pembrolizumab.


Clinical Study Identifier: s17-00867
ClinicalTrials.gov Identifier: NCT03313778
Principal Investigator: Janice Mehnert.
Other Investigators: Nila Theresa De La Rosa, Elaine Shum, Scot Niglio, Vamsidhar Velcheti, Eneil De La Pena, Maya Dimitrova, Jeffrey S. Weber, Salman Rafi Punekar, Joshua K Sabari, Keriann M Scavone, Nina Beri, Avital Benson, Caitlin Elizabeth Ryan, David R. Wise, Jessica Wang, Paul E. Oberstein, Zujun Li, Samantha VanMaanen, Kristen Spencer, Kathleen M Madden, Nancy Chan, Douglas K Marks.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.